Every 10-Q that Sarepta Therapeutics,, Inc. (SRPT) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow SRPT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SRPT filings page.
Sarepta Therapeutics, a commercial-stage rare disease biotech focused on RNA and gene therapies, reported Q2 2026 total revenues of $401.3 million, down from $611.1 million a year earlier. The quarter showed a small net loss of $4.9 million (basic and diluted loss per share of $0.05), compared with net income of $196.9 million in Q2 2025. For the first six months of 2026, total revenues were $1.13 billion and net income was $326.1 million (basic EPS $3.10), versus a loss of $250.6 million in the prior-year period. Results include a $39.0 million litigation contingency charge and $11.6 million write-down of obsolete ELEVIDYS inventory.
Net product revenues for the first half of 2026 were $659.2 million, including $459.1 million from PMO exon-skipping products and $200.1 million from ELEVIDYS. Collaboration and other revenue benefited from the Roche agreement, with $365.0 million recognized in the first half, including $325.0 million from an unexercised option and a $40.0 million milestone for the first commercial patient in Japan. As of June 30, 2026, Sarepta held $945.0 million in cash, cash equivalents, restricted cash and investments and total stockholders’ equity of $1.53 billion, and believed available resources and its revolving credit facility are sufficient to fund its operational plan for at least twelve months. ELEVIDYS carries a boxed warning for acute liver injury and is currently labeled only for ambulatory patients; Sarepta is running additional studies, including sirolimus-based immunosuppression for non-ambulatory patients, and intends to discuss a potential path to resume dosing in that population with the FDA.
Sarepta Therapeutics (SRPT) reported Q3 2025 results. Total revenues were $399.4 million versus $467.2 million a year ago, with product revenues of $370.0 million and collaboration and other revenues of $29.3 million. ELEVIDYS U.S. product revenue was $131.5 million versus $181.0 million, and PMO product revenues were $238.5 million versus $248.8 million.
The company posted an operating loss of $103.4 million and a net loss of $179.9 million for the quarter. Year to date, total revenues reached $1.76 billion versus $1.24 billion, but the company recorded a net loss of $430.6 million driven by a $583.6 million acquired IPR&D expense from the Arrowhead deal and a $138.6 million loss on debt extinguishment tied to a 2027-to-2030 notes exchange.
Cash and cash equivalents were $613.1 million, with short‑term investments of $237.9 million. Deferred revenue current portion rose to $485.4 million. The company repurchased $25.3 million of stock under a $500 million authorization. Sarepta suspended commercial shipments of ELEVIDYS to non‑ambulatory patients in June 2025 and is in ongoing FDA discussions regarding a labeling supplement, including a boxed warning for acute liver injury and acute liver failure and removal of the non‑ambulatory population from Indication and Usage.